Futura医薬品株式は11%上昇し,小さな試験でWSD4000ゲルが著しく改善された. Futura Medical shares rose 11% after a small trial showed its WSD4000 gel significantly improved female sexual function.

2026年1月12日,女性性機能障害に対するWSD4000ゲルの小規模な試験から有望な初期結果が報告された後,Futura Medical PLCの株価は11%上昇して1.45pとなった. Futura Medical PLC shares rose 11% to 1.45p on January 12, 2026, after the company reported promising early results from a small trial of its WSD4000 gel for female sexual dysfunction. 12人の女性とFDAのガイドラインに係る研究では,性機能の"高い統計的改善"が示され,平均的にFSFIスコアは6.35点増した. The study, involving 12 women and following FDA guidelines, showed “highly statistically significant” improvements in sexual function, with an average FSFI score increase of 6.35 points—exceeding the clinically meaningful threshold. 結果は,前項に掲げる期間において,投資家の関心を生み出しており,過度の療養の潜在性を示唆している. The results, while preliminary, have generated investor interest and suggest potential for an over-the-counter treatment. 会社は早期調査を通じて製品を推進し続けている. The company continues advancing the product through early-stage research.